{"title":"钙结合光蛋白 clytin II:在中国仓鼠卵巢-K1 细胞中表达优选的人类密码子优化的 clytin II 基因及其在 G 蛋白偶联受体检测中的应用。","authors":"Satoshi Inouye , Jun-ichi Sato , Yuiko Sahara-Miura , Sunao Hisada","doi":"10.1016/j.pep.2024.106481","DOIUrl":null,"url":null,"abstract":"<div><p>Clytin II (CLII) is a Ca<sup>2+</sup>-binding photoprotein and has been identified as an isotype of clytin I (CLI). CLII consists of apoCLII (an apoprotein) and 2-peroxide of coelenterazine (an adduct of molecular oxygen to coelenterazine), which is identical to the widely used Ca<sup>2+</sup>-binding photoprotein, aequorin (AQ). However, CLII triggered by Ca<sup>2+</sup> exhibits a 4.5-fold higher maximum luminescence intensity (<em>I</em><sub>max</sub>) compared to both AQ and CLI, and it is approximately 5 times less sensitive to Ca<sup>2+</sup> than AQ. To confirm the suitability of the preferred human codon-optimized CLII (pCLII) gene for cell-based G-protein-coupled receptor (GPCR) assays, a transformant stably expressing apoprotein of pCLII using the pCLII gene in the mitochondria of CHO–K1 cells was established and <em>in situ</em> regenerated pCLII in the cells were applied to the high-throughput screening system. An ATP-stimulated GPCR assay for endogenous P2Y purinergic receptors was confirmed using the established stable transformant.</p></div>","PeriodicalId":20757,"journal":{"name":"Protein expression and purification","volume":"220 ","pages":"Article 106481"},"PeriodicalIF":1.4000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The calcium-binding photoprotein clytin II: Expression of the preferred human codon-optimized clytin II gene in Chinese hamster ovary-K1 cells and its use in the G-protein-coupled receptor assays\",\"authors\":\"Satoshi Inouye , Jun-ichi Sato , Yuiko Sahara-Miura , Sunao Hisada\",\"doi\":\"10.1016/j.pep.2024.106481\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Clytin II (CLII) is a Ca<sup>2+</sup>-binding photoprotein and has been identified as an isotype of clytin I (CLI). CLII consists of apoCLII (an apoprotein) and 2-peroxide of coelenterazine (an adduct of molecular oxygen to coelenterazine), which is identical to the widely used Ca<sup>2+</sup>-binding photoprotein, aequorin (AQ). However, CLII triggered by Ca<sup>2+</sup> exhibits a 4.5-fold higher maximum luminescence intensity (<em>I</em><sub>max</sub>) compared to both AQ and CLI, and it is approximately 5 times less sensitive to Ca<sup>2+</sup> than AQ. To confirm the suitability of the preferred human codon-optimized CLII (pCLII) gene for cell-based G-protein-coupled receptor (GPCR) assays, a transformant stably expressing apoprotein of pCLII using the pCLII gene in the mitochondria of CHO–K1 cells was established and <em>in situ</em> regenerated pCLII in the cells were applied to the high-throughput screening system. An ATP-stimulated GPCR assay for endogenous P2Y purinergic receptors was confirmed using the established stable transformant.</p></div>\",\"PeriodicalId\":20757,\"journal\":{\"name\":\"Protein expression and purification\",\"volume\":\"220 \",\"pages\":\"Article 106481\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Protein expression and purification\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1046592824000536\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Protein expression and purification","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1046592824000536","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
摘要
Clytin II(CLII)是一种结合 Ca2+ 的光蛋白,已被确定为 Clytin I(CLI)的同种型。CLII 由 apoCLII(一种载体蛋白)和 2-peroxide of coelenterazine(一种分子氧与 coelenterazine 的加合物)组成,与广泛使用的 Ca2+ 结合光蛋白 aequorin(AQ)相同。然而,与 AQ 和 CLI 相比,由 Ca2+ 触发的 CLII 的最大发光强度(Imax)高出 4.5 倍,而且它对 Ca2+ 的敏感性比 AQ 低约 5 倍。为了证实优选的人类密码子优化 CLII(pCLII)基因适用于基于细胞的 G 蛋白偶联受体(GPCR)检测,在 CHO-K1 细胞线粒体中建立了使用 pCLII 基因稳定表达 pCLII 蛋白的转化体,并将细胞中原位再生的 pCLII 应用于高通量筛选系统。利用已建立的稳定转化体,对内源性 P2Y 嘌呤能受体进行了 ATP 刺激的 GPCR 检测。
The calcium-binding photoprotein clytin II: Expression of the preferred human codon-optimized clytin II gene in Chinese hamster ovary-K1 cells and its use in the G-protein-coupled receptor assays
Clytin II (CLII) is a Ca2+-binding photoprotein and has been identified as an isotype of clytin I (CLI). CLII consists of apoCLII (an apoprotein) and 2-peroxide of coelenterazine (an adduct of molecular oxygen to coelenterazine), which is identical to the widely used Ca2+-binding photoprotein, aequorin (AQ). However, CLII triggered by Ca2+ exhibits a 4.5-fold higher maximum luminescence intensity (Imax) compared to both AQ and CLI, and it is approximately 5 times less sensitive to Ca2+ than AQ. To confirm the suitability of the preferred human codon-optimized CLII (pCLII) gene for cell-based G-protein-coupled receptor (GPCR) assays, a transformant stably expressing apoprotein of pCLII using the pCLII gene in the mitochondria of CHO–K1 cells was established and in situ regenerated pCLII in the cells were applied to the high-throughput screening system. An ATP-stimulated GPCR assay for endogenous P2Y purinergic receptors was confirmed using the established stable transformant.
期刊介绍:
Protein Expression and Purification is an international journal providing a forum for the dissemination of new information on protein expression, extraction, purification, characterization, and/or applications using conventional biochemical and/or modern molecular biological approaches and methods, which are of broad interest to the field. The journal does not typically publish repetitive examples of protein expression and purification involving standard, well-established, methods. However, exceptions might include studies on important and/or difficult to express and/or purify proteins and/or studies that include extensive protein characterization, which provide new, previously unpublished information.